Evidence map›Paper›PMID 35657681›Full record

ArticleMetallomics : integrated biometal science2022

Rhenium(I) conjugates as tools for tracking cholesterol in cells.

Joanna Lazniewska, Christie Bader, Shane M Hickey, Stavros Selemidis, John O'Leary, Peter V Simpson, Stefano Stagni, Sally E Plush, Massimiliano Massi, Doug Brooks

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metallomics : integrated biometal science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Joanna LazniewskaUniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia 5001, Australia.ORCID 0000-0001-5729-4773
Christie BaderUniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia 5001, Australia.
Shane M HickeyUniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia 5001, Australia.
Stavros SelemidisDepartment of Human Biosciences, RMIT University, Melbourne, Victoria 3000, Australia.
John O'LearyDiscipline of Histopathology, University of Dublin Trinity College, Dublin 2, Ireland.
Peter V SimpsonSchool of Molecular and Life Sciences - Curtin University, Bentley, Western Australia 6102, Australia.
Stefano StagniDepartment of Industrial Chemistry Toso Montanari, University of Bologna, Via Zamboni, 33, Bologna I-40136, Italy.
Sally E PlushUniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia 5001, Australia.
Massimiliano MassiSchool of Molecular and Life Sciences - Curtin University, Bentley, Western Australia 6102, Australia.
Doug BrooksUniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia 5001, Australia.
University of South Australia · AUCurtin University · AURMIT University · AUTrinity College Dublin · IEZambon (Italy) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholesterol is vital to control membrane integrity and fluidity, but is also a precursor to produce steroid hormones, bile acids, and vitamin D. Consequently, altered cholesterol biology has been linked to many diseases, including metabolic syndromes and cancer. Defining the intracellular pools of cholesterol and its trafficking within cells is essential to understand both normal cell physiology and mechanisms of pathogenesis. We have synthesized a new cholesterol mimic (ReTEGCholestanol), comprising a luminescent rhenium metal complex and a cholestanol targeting unit, linked using a tetraethylene glycol (TEG) spacer. ReTEGCholestanol demonstrated favourable imaging properties and improved water solubility when compared to a cholesterol derivative, and structurally related probes lacking the TEG linker. A non-malignant and three malignant prostate cell lines were used to characterize the uptake and intracellular distribution of ReTEGCholestanol. The ReTEGCholestanol complex was effectively internalized and mainly localized to late endosomes/lysosomes in non-malignant PNT1a cells, while in prostate cancer cells it also accumulated in early endosomes and multivesicular bodies, suggesting disturbed cholesterol biology in the malignant cells. The ReTEGCholestanol is a novel imaging agent for visualizing endosomal uptake and trafficking, which may be used to define cholesterol related biology including membrane integration and altered lipid trafficking/processing.

Indexed as

RheniumCell MembraneCholesterolEndosomesLysosomesCholesterolRheniumCholesterolendosomal pathwayluminescenceprostate cancerrhenium(I) complex

Identifiers

PMID35657681
PMCPMC9344854
OpenAlexW4281961376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.